Tokyo, December 13, 2013 - Astellas Pharma Inc. (“Astellas”; headquarters : Tokyo:4503; President and CEO: Yoshihiko Hatanaka), today announced that a definitive agreement has been concluded between Astellas Pharma Tech Co., Ltd. (“Astellas Pharma Tech”; headquarters: Tokyo; President : Takashi Shimizu), Astellas’ production subsidiary in Japan, and Nichi-Iko Pharmaceutical Co., Ltd. (“Nichi-Iko”; headquarters : Toyama; President and CEO: Yuichi Tamura), under which Nichi-Iko will succeed to the business of Fuji Plant (Fuji-shi, Shizuoka), one of production sites of Astellas Pharma Tech on April 1, 2014 by Company Split.

Astellas and Nichi-Iko has entered into a basic agreement as announced on September 27, 2013.